This category page catalogs biotechnology and pharmaceutical companies developing therapies targeting WNT signaling, Hedgehog signaling, and other developmental pathways for Alzheimer's disease (AD). These pathways play critical roles in neurodevelopment, synaptic plasticity, neurogenesis, and neuronal survival — making them attractive targets for disease-modifying AD therapies.
The therapeutic approaches include:
| WNT Agonists | Preclinical/Phase 1 |
|---|---|
| DKK1 Inhibitors | Phase 2 |
| Beta-catenin Stabilizers | Preclinical |
| Hedgehog Modulators | Preclinical |
| Neurogenesis Activators | Phase 1/2 |
The WNT signaling pathway is critically involved in AD pathogenesis:
| Factor | Evidence | Therapeutic Implication |
|---|---|---|
| DKK1 Elevation | 2-3x elevated in AD brains | DKK1 neutralization |
| Beta-catenin Loss | Reduced nuclear beta-catenin in AD | Stabilization |
| Wnt3a Deficiency | Impaired in AD models | WNT3a replacement |
| Frizzled Dysregulation | Altered FZD expression | Receptor modulators |
Adult hippocampal neurogenesis is compromised in AD:
The Hedgehog signaling pathway regulates:
NeuroWNT Pharma (Research Stage)
Academic Programs:
DKK1-Targeting Approaches
DKK1 (Dickkopf-1) is the major endogenous WNT antagonist elevated in AD:
| Company | Compound | Mechanism | Status |
|---|---|---|---|
| Multiple Academic Groups | Anti-DKK1 antibodies | Neutralizing antibody | Preclinical |
| Pharmaceutical Partners | DKK1 siRNA | Gene silencing | Preclinical |
Research References:
Approach: Stabilize beta-catenin to promote WNT pathway activity
| Company/Group | Compound | Status |
|---|---|---|
| Academic Consortium | Small molecule stabilizers | Preclinical |
| Multiple Pharma | GSK3 inhibitors (indirect) | Phase 1/2 |
Note: GSK3 inhibitors like CHIR99021 indirectly activate WNT/beta-catenin by inhibiting GSK3beta-mediated degradation.
Research Stage Programs:
Academic Research:
Several companies target neurogenesis for AD:
Aspen Neuroscience
Lineage Cell Therapeutics
Neuralstem Inc. (Historical)
See also: AD Neurotrophin Growth Factor Companies
Companies targeting BDNF and other neurotrophic factors that intersect with developmental pathways:
| Company | Approach | Target | Status |
|---|---|---|---|
| Amgen | BDNF mimics | TrkB | Preclinical |
| Genentech | TrkB agonists | TrkB | Phase 1 |
| Farmalabor | BDNF delivery | TrkB | Research |
| Approach | Companies | Stage | AD-Specific Trials |
|---|---|---|---|
| WNT Protein Therapy | NeuroWNT, Academic | Preclinical | None |
| DKK1 Inhibition | Multiple | Preclinical | None |
| Beta-catenin Stabilizers | Academic | Preclinical | None |
| Hedgehog Modulators | Research | Preclinical | None |
| Neurogenesis (Cell) | Aspen, Lineage | Phase 1/2 | PD-focused |
| Neurotrophic Factors | Amgen, Genentech | Phase 1 | Some AD |